Uterine treatment device developer Interlace Medical sees $20.5m in Series C funding | AltAssets Private Equity News

Subscribe today

Advanced
Search

Uterine treatment device developer Interlace Medical sees $20.5m in Series C funding

15 Jun 2009

Interlace Medical, a US medical device company, has raised $20.5m in Series C financing. The proceeds will be used to begin commercialisation of the MyoSure system, a minimally invasive treatment to remove intrauterine fibroids and polyps.

Sorry, to read the full story you must be a Premium Subscriber

Are you a subscriber?

In order to view premium content you need to be a Premium Subscriber. You can subscribe now to access premium online content.

Become a Premium Subscriber
for only £150 / €180 / $225 p.a.

Login area

If you are already a AltAssets subscriber please log in below.